MedTrace Logo

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

NCT01509755 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2017-01-24

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.

Conditions

Interventions

DRUG

placebo

Once daily injection, under the skin (s.c.) for 12 weeks

DRUG

liraglutide

Once daily injection, under the skin (s.c.) for 12 weeks

DRUG

glimepiride

Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452), MD · Novo Nordisk A/S

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2001-10-31
Completion
2001-10-31

Countries

  • Denmark
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01509755 on ClinicalTrials.gov